Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Delanoy, N, Hardy-Bessard, A-C, Efstathiou, E, Le Moulec, S, Basso, U, Birtle, A, Thomson, A, Krainer, M, Guillot, A, De Giorgi, U, Hasbini, A, Daugaard, G, Bahl, A, Chowdhury, S, Caffo, O, Beuzeboc, P, Spaeth, D, Eymard, J-C, Fléchon, A, Alexandre, J, Helissey, C, Butt, M, Priou, F, Lechevallier, E, Deville, J-L, Gross-Goupil, M, Morales, R, Thiery-Vuillemin, A, Gavrikova, T, Barthélémy, P, Sella, A, Fizazi, K, Ferrero, J-M, Laguerre, B, Thibault, C, Hans, S & Oudard, S 2020, 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database' European journal of cancer (Oxford, England : 1990), vol. 125, pp. 153-163. https://doi.org/10.1016/j.ejca.2019.10.030

APA

CBE

Delanoy N, Hardy-Bessard A-C, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard J-C, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville J-L, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero J-M, Laguerre B, Thibault C, Hans S, Oudard S. 2020. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. European journal of cancer (Oxford, England : 1990). 125:153-163. https://doi.org/10.1016/j.ejca.2019.10.030

MLA

Vancouver

Author

Delanoy, Nicolas ; Hardy-Bessard, Anne-Claire ; Efstathiou, Eleni ; Le Moulec, Sylvestre ; Basso, Umberto ; Birtle, Alison ; Thomson, Alastair ; Krainer, Michael ; Guillot, Aline ; De Giorgi, Ugo ; Hasbini, Ali ; Daugaard, Gedske ; Bahl, Amit ; Chowdhury, Simon ; Caffo, Orazio ; Beuzeboc, Philippe ; Spaeth, Dominique ; Eymard, Jean-Christophe ; Fléchon, Aude ; Alexandre, Jerome ; Helissey, Carole ; Butt, Mohamed ; Priou, Frank ; Lechevallier, Eric ; Deville, Jean-Laurent ; Gross-Goupil, Marine ; Morales, Rafael ; Thiery-Vuillemin, Antoine ; Gavrikova, Tatiana ; Barthélémy, Philippe ; Sella, Avishay ; Fizazi, Karim ; Ferrero, Jean-Marc ; Laguerre, Brigitte ; Thibault, Constance ; Hans, Sophie ; Oudard, Stéphane. / Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer : The CATS international database. In: European journal of cancer (Oxford, England : 1990). 2020 ; Vol. 125. pp. 153-163.

Bibtex

@article{734ea8b117d44050b9a213ac24d08866,
title = "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database",
abstract = "AIM OF THE STUDY: Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry.METHODS: The 669 consecutive mCRPC patients of the CATS registry were classified according to their type of progression at initiation of each LET: PSA only (PSA-p), radiological (±PSA) (Radio-p); or clinical (±PSA, ±radiological) progression (Clin-p). Overall survival (OS), the primary endpoint, was calculated from initiation of the first-, second- and third-LET to death for each sequence.RESULTS: Median OS was shorter in the Clin-p group compared with the PSA-p group (14-month difference in first line; around 7-month difference in second- and third line). Shorter progression-free survival (PFS) was also observed in Clin-p patients, whatever the treatment is. Clinical progression seemed to be associated with a shorter duration of therapy with androgen receptor-targeted therapy (ART) compared with taxanes.CONCLUSIONS: Clinical progression at initiation of a LET is associated with poor outcomes including shorter PFS and OS as well as clinical and biological features of aggressive disease. Stratifying patients in clinical trials according to disease progression type may prevent selection bias and data heterogeneity. In daily practice, first signs of clinical progression may prompt physicians to consider starting a new LET, independently of PSA levels.",
author = "Nicolas Delanoy and Anne-Claire Hardy-Bessard and Eleni Efstathiou and {Le Moulec}, Sylvestre and Umberto Basso and Alison Birtle and Alastair Thomson and Michael Krainer and Aline Guillot and {De Giorgi}, Ugo and Ali Hasbini and Gedske Daugaard and Amit Bahl and Simon Chowdhury and Orazio Caffo and Philippe Beuzeboc and Dominique Spaeth and Jean-Christophe Eymard and Aude Fl{\'e}chon and Jerome Alexandre and Carole Helissey and Mohamed Butt and Frank Priou and Eric Lechevallier and Jean-Laurent Deville and Marine Gross-Goupil and Rafael Morales and Antoine Thiery-Vuillemin and Tatiana Gavrikova and Philippe Barth{\'e}l{\'e}my and Avishay Sella and Karim Fizazi and Jean-Marc Ferrero and Brigitte Laguerre and Constance Thibault and Sophie Hans and St{\'e}phane Oudard",
note = "Copyright {\circledC} 2019 Elsevier Ltd. All rights reserved.",
year = "2020",
month = "1",
doi = "10.1016/j.ejca.2019.10.030",
language = "English",
volume = "125",
pages = "153--163",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer

T2 - The CATS international database

AU - Delanoy, Nicolas

AU - Hardy-Bessard, Anne-Claire

AU - Efstathiou, Eleni

AU - Le Moulec, Sylvestre

AU - Basso, Umberto

AU - Birtle, Alison

AU - Thomson, Alastair

AU - Krainer, Michael

AU - Guillot, Aline

AU - De Giorgi, Ugo

AU - Hasbini, Ali

AU - Daugaard, Gedske

AU - Bahl, Amit

AU - Chowdhury, Simon

AU - Caffo, Orazio

AU - Beuzeboc, Philippe

AU - Spaeth, Dominique

AU - Eymard, Jean-Christophe

AU - Fléchon, Aude

AU - Alexandre, Jerome

AU - Helissey, Carole

AU - Butt, Mohamed

AU - Priou, Frank

AU - Lechevallier, Eric

AU - Deville, Jean-Laurent

AU - Gross-Goupil, Marine

AU - Morales, Rafael

AU - Thiery-Vuillemin, Antoine

AU - Gavrikova, Tatiana

AU - Barthélémy, Philippe

AU - Sella, Avishay

AU - Fizazi, Karim

AU - Ferrero, Jean-Marc

AU - Laguerre, Brigitte

AU - Thibault, Constance

AU - Hans, Sophie

AU - Oudard, Stéphane

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2020/1

Y1 - 2020/1

N2 - AIM OF THE STUDY: Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry.METHODS: The 669 consecutive mCRPC patients of the CATS registry were classified according to their type of progression at initiation of each LET: PSA only (PSA-p), radiological (±PSA) (Radio-p); or clinical (±PSA, ±radiological) progression (Clin-p). Overall survival (OS), the primary endpoint, was calculated from initiation of the first-, second- and third-LET to death for each sequence.RESULTS: Median OS was shorter in the Clin-p group compared with the PSA-p group (14-month difference in first line; around 7-month difference in second- and third line). Shorter progression-free survival (PFS) was also observed in Clin-p patients, whatever the treatment is. Clinical progression seemed to be associated with a shorter duration of therapy with androgen receptor-targeted therapy (ART) compared with taxanes.CONCLUSIONS: Clinical progression at initiation of a LET is associated with poor outcomes including shorter PFS and OS as well as clinical and biological features of aggressive disease. Stratifying patients in clinical trials according to disease progression type may prevent selection bias and data heterogeneity. In daily practice, first signs of clinical progression may prompt physicians to consider starting a new LET, independently of PSA levels.

AB - AIM OF THE STUDY: Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry.METHODS: The 669 consecutive mCRPC patients of the CATS registry were classified according to their type of progression at initiation of each LET: PSA only (PSA-p), radiological (±PSA) (Radio-p); or clinical (±PSA, ±radiological) progression (Clin-p). Overall survival (OS), the primary endpoint, was calculated from initiation of the first-, second- and third-LET to death for each sequence.RESULTS: Median OS was shorter in the Clin-p group compared with the PSA-p group (14-month difference in first line; around 7-month difference in second- and third line). Shorter progression-free survival (PFS) was also observed in Clin-p patients, whatever the treatment is. Clinical progression seemed to be associated with a shorter duration of therapy with androgen receptor-targeted therapy (ART) compared with taxanes.CONCLUSIONS: Clinical progression at initiation of a LET is associated with poor outcomes including shorter PFS and OS as well as clinical and biological features of aggressive disease. Stratifying patients in clinical trials according to disease progression type may prevent selection bias and data heterogeneity. In daily practice, first signs of clinical progression may prompt physicians to consider starting a new LET, independently of PSA levels.

U2 - 10.1016/j.ejca.2019.10.030

DO - 10.1016/j.ejca.2019.10.030

M3 - Journal article

VL - 125

SP - 153

EP - 163

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

ER -

ID: 59003708